Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
Advances in genetics, pharmacology, and an improved understanding of molecular mechanisms have enabled the treatment of debilitating neurodegenerative diseases with high precision. Among the various cutting-edge treatment approaches, antisense oligonucleotides (ASOs) represent a promising approach by enabling reductions or modifications in RNA and protein expression.
Approved ASO therapies for Neurodegenerative and Neuromuscular Diseases